Page 150 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)

2- Ezetimibe

 New lipid lowering agent.

 MOA

 Blocks intestinal absorption of cholesterol→ cholesterol (Total and LDL) levels in
the blood.
 intestinal cholesterol absorption →  cholesterol levels in the liver which

compensated by  cholesterol synthesis in the liver
 Decreased cholesterol pool in the liver is compensated by shifting LDL from the
blood into the liver.

 Administered in combination with statins, fibrates
 Adverse effects:

 headache, rash
 Contraindications:

 patients with active liver disease

Used as adjunctive therapy with statin (LFTs require monitoring)

| P a g e - 134 -